Kailera Therapeutics valuation, funding and investors
Kailera Therapeutics works in biopharmaceutical research and development, based in Waltham, United States. It has about 26 employees.
- Last round
- Series B · $600M · Oct 2025
- Valuation at last round
- $3.68B · implied
- Headcount
- 26
- Grade
- B
- Founded
- –
Kailera Therapeutics valuation today
VCMC values Kailera Therapeutics at $5.5B today, with a range of $2.6B to $7.8B and a grade of B. The valuation starts from its last funding round, a Series B round in Oct 2025.
Valuation by date (28 rows)
Each point is what the model would have shown on that date, using only what was known then; before its first round, a company is valued as a startup because it later raised.
| Date | Valuation | Range | Predicted in 1 yr | Phase | Headcount | Trend | Grade | Winding-down probability |
|---|---|---|---|---|---|---|---|---|
| 1 Oct 2024 | $1.5B | $1.3B – $3.1B | $2.7B (+80%) | after a round | – | unknown | B | 0% |
| 2 Oct 2024 | $1.5B | $1.3B – $3.1B | $2.7B (+80%) | after a round | – | unknown | B | 0% |
| 1 Nov 2024 | $1.6B | $1.3B – $3.1B | $2.7B (+71%) | after a round | – | unknown | B | 0% |
| 1 Dec 2024 | $1.7B | $1.3B – $3.1B | $2.7B (+63%) | after a round | 26 | unknown | B | 0% |
| 1 Jan 2025 | $1.7B | $1.3B – $3.1B | $2.7B (+55%) | after a round | 26 | unknown | B | 0% |
| 1 Feb 2025 | $1.8B | $1.3B – $3.1B | $2.7B (+48%) | after a round | 26 | unknown | B | 0% |
| 1 Mar 2025 | $1.9B | $1.3B – $3.1B | $2.7B (+41%) | after a round | 26 | unknown | B | 0% |
| 1 Apr 2025 | $2.0B | $1.3B – $3.1B | $2.7B (+34%) | after a round | 26 | unknown | B | 0% |
| 1 May 2025 | $2.1B | $1.3B – $3.1B | $2.7B (+28%) | after a round | 26 | unknown | B | 0% |
| 1 Jun 2025 | $2.2B | $1.3B – $3.1B | $2.7B (+22%) | after a round | 26 | unknown | B | 0% |
| 1 Jul 2025 | $2.3B | $1.3B – $3.1B | $2.7B (+16%) | after a round | 26 | unknown | B | 0% |
| 1 Aug 2025 | $2.4B | $1.3B – $3.1B | $2.7B (+10%) | after a round | 26 | unknown | B | 0% |
| 1 Sep 2025 | $2.6B | $1.3B – $3.1B | $2.7B (+5%) | after a round | 26 | unknown | B | 0% |
| 1 Oct 2025 | $2.7B | $1.3B – $3.1B | $2.7B (0%) | after a round | 26 | unknown | B | 0% |
| 15 Oct 2025 | $3.7B | $2.6B – $7.8B | $5.5B (+50%) | after a round | 26 | unknown | B | 0% |
| 1 Nov 2025 | $3.8B | $2.6B – $7.8B | $5.5B (+47%) | after a round | 26 | unknown | B | 0% |
| 1 Dec 2025 | $3.9B | $2.6B – $7.8B | $5.5B (+42%) | after a round | 26 | unknown | B | 0% |
| 1 Jan 2026 | $4.0B | $2.6B – $7.8B | $5.5B (+37%) | after a round | 26 | unknown | B | 0% |
| 1 Feb 2026 | $4.2B | $2.6B – $7.8B | $5.5B (+33%) | after a round | 26 | unknown | B | 0% |
| 1 Mar 2026 | $4.3B | $2.6B – $7.8B | $5.5B (+29%) | after a round | 26 | unknown | B | 0% |
| 1 Apr 2026 | $4.4B | $2.6B – $7.8B | $5.5B (+24%) | after a round | 26 | unknown | B | 0% |
| 1 May 2026 | $4.6B | $2.6B – $7.8B | $5.5B (+20%) | after a round | 26 | unknown | B | 0% |
| 1 Jun 2026 | $4.8B | $2.6B – $7.8B | $5.5B (+16%) | after a round | 26 | unknown | B | 0% |
| 1 Jul 2026 | $4.9B | $2.6B – $7.8B | $5.5B (+12%) | after a round | 26 | unknown | B | 0% |
| 1 Aug 2026 | $5.1B | $2.6B – $7.8B | $5.5B (+9%) | after a round | 26 | unknown | B | 0% |
| 1 Sep 2026 | $5.3B | $2.6B – $7.8B | $5.5B (+5%) | after a round | 26 | unknown | B | 0% |
| 1 Oct 2026 | $5.4B | $2.6B – $7.8B | $5.5B (+1%) | after a round | 26 | unknown | B | 0% |
| 24 Oct 2026 | $5.5B | $2.6B – $7.8B | $5.5B (0%) | after a round | 26 | unknown | B | 0% |
Key facts about Kailera Therapeutics
- Founded
- Not on record
- Headquarters
- Waltham, United States
- Employees
- about 26
- Total raised
- $1.00B
- Funding rounds
- 2
- Last round
- Series B Oct 2025
Kailera Therapeutics funding history
Kailera Therapeutics has 2 funding rounds on record, from Oct 2024 to Oct 2025, $1.00B in total. The latest disclosed valuation is $1.50B post-money (Series A, Oct 2024).
Series B 14 Oct 2025
Led by Bain Capital Private Equity; with Adage Capital Management LP, Canada Pension Plan Investment Board, Invus, Janus Henderson Investors, Perseverance Capital, Qatar Investment Authority, Royalty Pharma, Citadel, T. Rowe Price Associates, Inc., Atlas Venture, Bain Capital Life Sciences, RTW Investments, Sirona Capital.
Sources: techstartups.com, investors.kailera.com, globenewswire.com and 1 more
$600M
Series A 1 Oct 2024
Led by Atlas Venture, Bain Capital Life Sciences, RTW Investments; with Lyra Capital.
Sources: investegate.co.uk, investors.kailera.com
$400M
$1.50B post-money
Kailera Therapeutics investors
15 investors have backed Kailera Therapeutics; Atlas Venture, Bain Capital Life Sciences and RTW Investments and 1 more led at least one round.
- Bain Capital Life Sciences lead, 2 rounds
- Adage Capital Management LP
- Canada Pension Plan Investment Board
- Invus
- Janus Henderson Investors
- Lyra Capital
- Perseverance Capital
- Qatar Investment Authority
- Sirona Capital
- T. Rowe Price Associates, Inc.
What Kailera Therapeutics does
Kailera Therapeutics works in pharmaceutical products, with 14 recorded offerings and customers in healthcare, biotechnology and pharmaceuticals.
Kailera Therapeutics, Inc. is a United States biopharmaceutical company engaged in the development of therapies for obesity and related conditions. The company focuses on clinical-stage injectable and oral treatments, including dual GLP-1/GIP receptor agonists and small molecule GLP-1 receptor agonists, with an emphasis on obesity and type 2 diabetes. Kailera Therapeutics is advancing its pipeline through global Phase 3 trials and serves the global healthcare market.
Description from Veridion's company data.
Products and services
- Biopharmaceutical Research and Development
- Obesity Therapy Development
- Type 2 Diabetes Therapy Development
- Injectable Therapy Development
- Oral Therapy Development
- Dual Receptor Agonist Development
- Small Molecule Agonist Development
- Clinical Trial Execution for Obesity Therapies
- Clinical Trial Execution for Diabetes Therapies
- Scientific and Technological Innovation Services
- Healthcare Technology Development
- Clinical Data Analysis and Interpretation Services
- Regulatory Submission Services
- Therapeutic Pipeline Advancement Services
Markets
- Healthcare
- Biotechnology
- Pharmaceuticals
Technology
- Dual GLP-1/GIP Receptor Agonist
- Small Molecule GLP-1 Receptor Agonist
Business model
- Manufacturing
Industry codes (NAICS)
- 541714 Research and Development in Biotechnology (except Nanobiotechnology) 100% match
Questions about Kailera Therapeutics
What is Kailera Therapeutics worth?
Valuation $5.5B (range $2.6B to $7.8B), as of 24 Oct 2026. The last disclosed valuation was $1.50B (Series A, Oct 2024).
Has Kailera Therapeutics raised money?
Kailera Therapeutics has 2 funding rounds on record, from Oct 2024 to Oct 2025, $1.00B in total. The latest disclosed valuation is $1.50B post-money (Series A, Oct 2024).
Who has invested in Kailera Therapeutics?
Atlas Venture, Bain Capital Life Sciences, RTW Investments, Bain Capital Private Equity, Adage Capital Management LP and Canada Pension Plan Investment Board, and 9 more. Lead investors include Atlas Venture, Bain Capital Life Sciences, RTW Investments and Bain Capital Private Equity.
How many people work at Kailera Therapeutics?
About 26.
What does Kailera Therapeutics do?
Kailera Therapeutics works in pharmaceutical products, with 14 recorded offerings and customers in healthcare, biotechnology and pharmaceuticals. Its main offerings are biopharmaceutical research and development, obesity therapy development and type 2 diabetes therapy development.
Where is Kailera Therapeutics based?
Kailera Therapeutics is based in Waltham, United States; its founding year is not on record. It has about 26 employees.